What is a Guardant 360 test?
Guardant360® is a liquid biopsy. This laboratory test is performed with a blood sample from cancer patients in an advanced stage (stage III or IV) in order to find an appropriate therapy option for a therapy with targeted drugs. Moreover Guardant360® can be used for monitoring and aftercare of a cancer therapy.
How many genes does Guardant 360 test?
Guardant360 detects cell-free circulating tumor DNA (ctDNA) in blood specimens of advanced solid-tumor cancer patients and evaluates 73 genes.
Is Guardant reveal FDA approved?
This is a different setting from the group’s only FDA-approved test, Guardant360 CDx, which is used to profile a patient’s tumour biomarkers….A test that tracks response to therapy is useful, but approval and reimbursement will be key.
| Guardant Health’s liquid biopsies | ||
|---|---|---|
| Test | Setting | Status |
How does Guardant reveal work?
These data show that Guardant Reveal can detect minimal residual disease from a simple blood draw. In addition, the sensitivity of the test increases with additional longitudinal blood draws, allowing for earlier detection of recurrence in the patient surveillance setting compared with standard imaging methods.
How accurate is Guardant 360?
The secured digital sequencing method of Guardant360® is 1000x more accurate than standard sequencing methods and results in a 99.9999% specificity.
Is Guardant 360 Next Generation Sequencing?
The Guardant360 CDx assay uses NGS technology to simultaneously detect mutations in 55 tumor genes, rather than one gene at a time.
Who owns Guardant health?
Number of employees : 864 people….2020.
| Name | Title |
|---|---|
| Helmy Eltoukhy | Chairman & Co-Chief Executive Officer |
| AmirAli H. Talasaz | President, Co-Chief Executive Officer & Director |
Is Guardant reveal covered by Medicare?
It has been trusted by more than 9,000 oncologists, with more than 150,000 tests performed to date, and is broadly covered by Medicare and many private payers, representing over 200 million lives.
Is Guardant 360 FDA approved?
The FDA has approved Guardant360, a liquid biopsy companion diagnostic for tumor mutation profiling or comprehensive genomic profiling to identify patients with locally advanced or metastatic non-small cell lung cancer who have a KRAS G12C mutation and may benefit from sotorasib.
Where is Guardant based?
REDWOOD CITY, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) — Guardant Health , Inc.
Who are Guardant Health competitors?
Guardant Health has 17 competitors. Guardant Health’s competitors are Freenome, Owlstone Medical, Strata Oncology, OncoHost, Thrive Earlier Detection and more.